Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 4(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06426758Not Yet Recruiting

Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation

Role: lead

NCT00917241Phase 4Completed

Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone

Role: lead

NCT01534169Phase 1Completed

Function of Regulatory T Cells Improved by Dexamethasone in Graves' Patients

Role: lead

All 3 trials loaded